Abeona Therapeutics Inc - Company Profile
Powered by 
All the data and insights you need on Abeona Therapeutics Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Abeona Therapeutics Inc Strategy Report
- Understand Abeona Therapeutics Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Abeona Therapeutics Inc (Abeona), formerly PlasmaTech Biopharmaceuticals Inc, is a biopharmaceutical company that develops and delivers gene therapy and plasma-based products for severe life-threatening rare diseases. The company’s lead programs include EB-101, ABO-101 and ABO-102 adeno-associated virus. Abeona develops EB-101 for recessive dystrophic epidermolysis bullosa (RDEB), EB-201 for epidermolysis bullosa (EB), ABO-202 (AAV-CLN1) gene therapy for the treatment of infantile Batten disease (INCL), ABO-201 (AAV-CLN3) gene therapy for Juvenile Batten disease (JNCL) and more. The company has partnerships for the commercialization of its products in the US, European Union, Switzerland, Norway, Iceland, Lichtenstein, Australia, New Zealand, China and South Korea. Abeona is headquartered in New York City, the US.
Headquarters
United States of America
Address
6555 Carnegie Ave, 4th Floor, Cleveland, Ohio, 44103
Website
abeonatherapeutics.com
Telephone
1 646 8134701
No of Employees
84
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABEO (NASD)
Revenue (2022)
$3.5M
147.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-36.5%
(2022 vs 2021)
Market Cap*
$182.8M
Net Profit Margin (2022)
XYZ
44.9%
(2022 vs 2021)
* As of and is in US$
Abeona Therapeutics Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Technologies: | AIM |
| AIM Capsid Technology | |
| Pipeline | |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Abeona Therapeutics Inc | Grifols SA | Jazz Pharmaceuticals Plc | Camurus AB | G1 Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | Spain | Ireland | Sweden | United States of America |
| City | Cleveland | Barcelona | Dublin | Lund | Research Triangle Park |
| State/Province | Ohio | Barcelona | - | - | North Carolina |
| No. of Employees | 84 | 23,744 | 2,800 | 213 | 100 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Michael Amoroso | Chairman | Executive Board | 2021 | 45 |
| Vishwas Seshadri, Ph.D. | Chief Executive Officer; Director; President | Executive Board | 2021 | 47 |
| Joseph Vazzano | Chief Financial Officer | Senior Management | 2022 | 39 |
| Brian Kevany, Ph.D. | Chief Technology Officer; Head - Research; Vice President | Senior Management | 2021 | - |
| Dmitriy Grachev | Chief Medical Officer | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer